Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
-
Rapid donor identification improves survival in high-risk first-remission patients with Acute Myeloid Leukemia
March 2021John M. Pagel, MD, PhD, Megan Othus, PhD, et al – Barriers to human leukocyte antigen (HLA) typing and cytogenetic testing can significantly impact the overall survival of patients newly diagnosed with acute myeloid leukemia (AML). In this landmark study, a concerted effort to address those issues and streamline the initiation of donor identification and referral for hematopoietic cell transplant (HCT) consultation in early disease state led to a higher CR1 transplantation rate and improved 2-year overall survival.
-
Updated evidence-based guidelines for optimal selection of unrelated donors and cord blood units for HCT
September 2019Dehn J, et al., Blood – A panel of immunogeneticists and other experts in the field of hematopoietic cell transplantation (HCT) has published updated evidence-based guidelines for the optimal selection of unrelated donors and cord blood units used for transplants.
The updated guidelines make recommendations for both HLA and non-HLA factors to consider in graft selection, including donor availability, donor age, patient sensitivity to HLA antigens, natural killer (NK) cell alloreactivity, and minimum total nucleated cell doses and CD34+ cell doses for cord blood units.
-
New Analysis Determines HLA Match Rates in Be The Match Registry
January 2016Buck K, et al. Biol Blood Marrow Transplant – A new analysis of the Be The Match Registry has determined that 7/8 HLA match rates are >80% for all four of the most frequent patient race/ethnic groups in the United States – White (WH), Hispanic (HIS), Asian/Pacific Islander (AIP), and African American (AFA). -
GVHD Marker Found in HLA-DPB1 Mismatched HCT
September 2015Petersdorf EW, et al. N Engl J Med –In this study of 2,029 transplants reported to CIBMTR (Center for International Blood and Marrow Transplant Research), researchers found that an HLA-DPB1 mismatch is not sufficient by itself to lead to GVHD, but is dependent upon specific DPB1 allele variations in both the donor and the recipient.